H.C. Wainwright lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $13 from $20 and keeps a Buy rating on the shares after the company announced the discontinuation of its independent development of FHD-286 in combination with decitabine for patients with relapsed and/or refractory acute myeloid leukemia. The firm is still believers in the BAF targeting thesis and sees Foghorns FHD-909 “as being able to still de-risk the strategy.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics price target lowered to $14 from $18 at Jefferies
- Foghorn Therapeutics Advances Precision Oncology Pipeline
- Foghorn to discontinue independent development of FHD-286 with decitabine in AML
- Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations
- Foghorn Therapeutics Reports Third Quarter Highlights